GISAR German Interdisciplinary Sarcoma Registry
GISAR
1 other identifier
observational
9,000
1 country
21
Brief Summary
GISAR has an open and modular setup. It is sought to include as many German sarcoma and CS patients (i.e. sarcoma and CS patients treated in Germany) in the registry as possible. A basic data set should be collected on every included patient). In order to adress specific scientific questions, additionally detailed data can be collected in defined patient groups (e.g. effectiveness / adverse effects of systemic therapies in defined situations) within the context of sub-project add-on modules. This data collection can be prospective or retrospective depending on the sub-project
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2018
Longer than P75 for all trials
21 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 29, 2018
CompletedFirst Submitted
Initial submission to the registry
October 8, 2019
CompletedFirst Posted
Study publicly available on registry
October 10, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2038
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2038
February 5, 2026
February 1, 2026
19.1 years
October 8, 2019
February 3, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Incidence of sarcoma preferably specific to the different subtypes
Generation of epidemiological data
1 year
Prevalence of sarcoma preferably specific to the different subtypes
Generation of epidemiological data
1 year
Prognosis of sarcoma preferably specific to the different subtypes
Generation of epidemiological data
1 year
Study Arms (1)
Patients with bone or soft tissue sarcomas or carcinosarcomas
Adults ≥18 years, verified for bone or soft tissue sarcomas including bone and soft tissue tumors with borderline histological results or with unclear histological dignity (like giant cell tumors of the bone \[GCTB\], desmoid tumors, atypical lipomatous tumors) as well as carcinosarcomas - independent of kind of therapy and therapy line. Thus, the registry is open for all subtypes of sarcomas and CS.
Eligibility Criteria
Adults ≥18 years, verified for bone or soft tissue sarcomas including bone and soft tissue tumors with borderline histological results or with unclear histological dignity (like giant cell tumors of the bone \[GCTB\], desmoid tumors, atypical lipomatous tumors) as well as carcinosarcomas - independent of kind of therapy and therapy line. Thus, the registry is open for all subtypes of sarcomas and CS.
You may qualify if:
- Histological verified bone or soft tissue sarcomas including bone and soft tissue tumors with borderline histological results or with unclear histological dignity like giant cell tumors of the bone (GCTB), desmoid tumors, atypical lipomatous tumors etc. - independent of therapy form and therapy line - or Histological verified sarcomatoid carcinomas/ carcinosarcomas: tumors with histological, cytological, or molecular properties of both epithelial tumors ("carcinoma") and mesenchymal tumors ("sarcoma") - independent of therapy form and therapy line.
- Signed informed consent form or equivalent (s. chapter 10)
- Age ≥18 years
You may not qualify if:
- none
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (21)
Universitätsklinikum Tübingen
Tübingen, Baden-Wurttemberg, 72076, Germany
Universitätsklinikum Erlangen
Erlangen, Bavaria, 91054, Germany
HELIOS Klinikum Bad Saarow
Bad Saarow, Germany
HELIOS Klinikum Berlin-Buch
Berlin, Germany
Vivantes Klinikum Berlin-Spandau
Berlin-Spandau, Germany
Universitätsklinikum Erlangen
Erlangen, Germany
Klinikum Frankfurt Höchst
Frankfurt, Germany
Krankenhaus Nordwest KHNW
Frankfurt, Germany
Uniklinik Freiburg
Freiburg im Breisgau, Germany
Universitätsmedizin Göttingen
Göttingen, Germany
Universitätsmedizin Greifswald
Greifswald, Germany
University Hospital Halle (Saale)
Halle, Germany
Asklepios Klinik St. Georg
Hamburg, 20099, Germany
Uniklinikum Leipzig
Leipzig, Germany
Universitätsmedizin Mainz
Mainz, Germany
Chirurgische Universitätsklinik Mannheim
Mannheim, Germany
Westfälische Wilhelms-Universität Münster
Münster, Germany
Klinikum Nürnberg
Nuremberg, Germany
Barmherzige Brüder Regensburg
Regensburg, Germany
Uniklinikum Regensburg
Regensburg, Germany
Universitätsklinikum Würzburg
Würzburg, Germany
Biospecimen
formalin-fixed paraffin-embedded tumor tissue
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Salah-Eddin Al-Batran, Prof. Dr
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 10 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 8, 2019
First Posted
October 10, 2019
Study Start
November 29, 2018
Primary Completion (Estimated)
January 1, 2038
Study Completion (Estimated)
January 1, 2038
Last Updated
February 5, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share
No IPD will be shared